Editing GSK plc (section)

===COVID-19 vaccine===
{{main article|Sanofi–GSK COVID-19 vaccine}}
In July 2020, the UK government signed up for 60 million doses of a [[COVID-19 vaccine]] developed by GSK and [[Sanofi]]. It uses a [[recombinant DNA|recombinant protein]]–based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021.<ref>{{Cite news |date=29 July 2020 |title=Coronavirus vaccine: UK signs deal with GSK and Sanofi |work=BBC News |url=https://www.bbc.com/news/business-53577637 |url-status=live |archive-url=https://web.archive.org/web/20200729070218/https://www.bbc.com/news/business-53577637 |archive-date=29 July 2020}}</ref> The company also agreed to a $2.1&nbsp;billion deal with the United States to produce 100 million doses of the vaccine.<ref>{{cite web |last=Lovelace Jr. |first=Berkeley |date=31 July 2020 |title=U.S. agrees to pay Sanofi and GSK $2.1&nbsp;billion for 100 million doses of coronavirus vaccine |url=https://www.cnbc.com/2020/07/31/us-agrees-to-pay-sanofi-and-gsk-2point1-billion-for-100-million-doses-of-coronavirus-vaccine.html |url-status=live |archive-url=https://web.archive.org/web/20200801234333/https://www.cnbc.com/2020/07/31/us-agrees-to-pay-sanofi-and-gsk-2point1-billion-for-100-million-doses-of-coronavirus-vaccine.html |archive-date=1 August 2020 |publisher=CNBC}}</ref>